UNITE Study: Understanding New Interventions With GBM ThErapy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for UNITE Study: Understanding New Interventions With GBM ThErapy (NCT03419403), a randomized phase 3 study. The primary outcome is Percentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management.

2. Clinical Question

3. Trial Design

The UNITE study, titled “Understanding New Interventions With GBM ThErapy,” was registered as NCT03419403. Its official title describes a Phase 3b study of management strategies for ocular side effects in participants with EGFR-amplified glioblastoma receiving depatuxizumab mafodotin. The registry phase classification is PHASE3. The study condition is glioblastoma multiforme, and AbbVie is listed as sponsor.

The design is recorded as randomized, parallel-group, and unmasked. Randomized allocation means assignment to the listed treatment strategies was intended to occur by chance. A parallel design assigns participants to a strategy rather than having each participant receive every strategy in sequence. The record does not report the randomization method, allocation concealment procedures, or details of how assignment was implemented. Because masking is listed as none, the study was open-label according to the registry field; further information about who knew assignments is not reported.

The three arm titles are Standard Steroids; Standard Steroids + Vasoconstrictor + Cold Compress; and Enhanced Steroids + Vasoconstrictor + Cold Compress. For the standard-steroid arm, the description specifies 1 drop in each eye 3 times/day, starting 2 days before infusion and continuing until 4 days after infusion, for a total of 7 days. The second arm includes the same steroid-drop schedule and vasoconstrictor drops and a cold compress. Its description is cut off during the vasoconstrictor instructions. The enhanced arm describes steroid drops 6 times/day, ophthalmic steroid ointment once daily before sleep, and the accompanying vasoconstrictor and cold-compress measures; its description is also incomplete. Complete administration instructions for every arm are not reported in the registry record.

Depatuxizumab mafodotin, temozolomide, and radiation are also listed as interventions. The registry enrollment is 40. The study start date is 2018-07-30, and the primary completion date is 2019-09-05. The status is terminated. The reason for termination and the timing of termination are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: All randomized participants

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety population: all randomized participants who received at least 1 dose of depatuxizumab mafodotin and had at least 1 post-baseline assessment within 8 weeks after the initial dose for either LogMAR or CEAE

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Safety population: All randomized participants who received at least 1 dose of depatuxizumab mafodotin

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management, measured over Within 8 weeks after the initial dose of depatuxizumab mafodotin.

The primary endpoint is the percentage of participants who required a change in ocular side-effect management within 8 weeks after the initial depatuxizumab mafodotin dose. The registry defines inadequate control as either a decline of at least 3 lines from baseline in visual acuity, corresponding to at least +0.3 on the LogMAR scale, or ocular side-effect severity of at least Grade 3 on the Corneal Epithelial Adverse Event scale. Baseline correction for visual acuity was determined at the screening ophthalmology visit.

This endpoint combines a functional measure of vision with a graded measure of corneal epithelial adverse events. It is intended to identify participants whose eye effects crossed a specified threshold for inadequate control and therefore required a management change. The registry’s operational definition matters: the endpoint is not simply any ocular symptom, any measured visual change, or any adverse event. It requires meeting either of the stated criteria.

The defined analysis population consists of randomized participants who received at least 1 dose of depatuxizumab mafodotin and had at least 1 post-baseline assessment within the specified 8-week period for either LogMAR or CEAE. The registry record does not report the number meeting the endpoint in each arm, the resulting percentages, confidence intervals, or a comparison between groups. Consequently, the definition can be interpreted, but the primary endpoint result cannot be evaluated from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is expressed as a percentage of participants with an event. In general, a percentage for a binary endpoint represents the proportion of an eligible analysis population classified as having the event. The event definition must be applied consistently, and the denominator must be specified, because a percentage can change depending on which participants are included. In this study, the registry defines the primary population as randomized participants who received at least 1 dose of depatuxizumab mafodotin and had at least 1 relevant post-baseline assessment within 8 weeks. The observed event counts and percentages are not reported in the registry record.

What does the endpoint classify?

The endpoint uses a threshold rule rather than treating every change in vision or every ocular effect as an event. A participant qualifies if visual acuity declines by at least 3 lines from baseline, equivalent to at least +0.3 on the LogMAR scale, or if ocular side-effect severity reaches at least Grade 3 on the CEAE scale. Using either criterion makes the endpoint sensitive to more than one clinically described feature, but it also means that the overall event rate would not by itself show which feature triggered classification. Separate component results would be needed to examine that question; they are not reported for the primary outcome.

In general, a confidence interval describes the range of effect values compatible with the observed data under a specified statistical method. Its width reflects precision: a wider interval indicates greater uncertainty, while a narrower interval indicates greater precision. A confidence interval for a difference between groups would help distinguish the estimated size of a difference from the uncertainty around that estimate. No primary-outcome confidence interval or group comparison is reported in the registry record, so the precision of the effect cannot be assessed.

How should a group comparison be understood?

For a binary endpoint, a comparison could be expressed using measures such as a difference in event percentages or a ratio of event probabilities. These measures answer different questions: a difference describes the separation between group percentages, while a ratio describes their relative scale. Such a comparison requires the event counts and denominators for the relevant groups, as well as an analysis method. No primary-outcome group values or analysis are reported, so no comparative measure can be interpreted for this trial.

Random assignment can help make groups comparable on average, but chance imbalances may remain, particularly in a small study. The registry enrollment is 40, and the adverse-event entries list group-specific numbers at risk of 14, 12, and 12 for the serious-event summaries. These entries should not be treated as primary-outcome denominators: the registry specifies a separate primary analysis population, and its arm-specific counts are not reported. The statistical plan, including whether any adjustment for baseline factors was planned, is not reported in the registry record.

Why do outcome definitions and follow-up matter?

The timeframe is part of the endpoint: the event is assessed within 8 weeks after the initial dose. A result for a different period would answer a different question. Similarly, the LogMAR component uses baseline correction determined at the screening ophthalmology visit, so the baseline reference is part of the event definition. The registry does not report the schedule of assessments, rules for assessments outside the window, or how a participant with one component measured but the other missing was classified.

In general, missing outcome data can affect both the estimated event rate and the comparability of groups. If missingness differs between arms or is related to ocular health, an analysis restricted to observed assessments may not represent all randomized participants. Statistical approaches can make different assumptions about missing outcomes, but the appropriate method depends on the data and prespecified plan. The missing-data strategy and the number of missing primary outcomes are not reported in the registry record.

In general, multiplicity arises when many outcomes, time points, or comparisons are examined. Repeated testing can increase the chance of at least one apparently notable finding. Prespecified outcome hierarchies or statistical adjustments are possible ways to address this, but the registry record does not report the multiplicity strategy. It lists 13 outcome measures and 0 analyses; the outcome count alone does not reveal which measures were formally tested or how results were handled.

The registry also provides no sample-size justification or statistical analysis plan. The reason for the enrollment target, the intended power, the planned test, any interim analyses, and any stopping boundaries are not reported in the registry record. General statistical principles cannot fill in those trial-specific details. Without the primary results and methods, the record permits interpretation of the endpoint definition, but not a reconstruction of the study’s inferential analysis.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 13 outcome measures, including the primary endpoint and secondary outcomes involving LogMAR change, time to bandage contact lens intervention, depatuxizumab mafodotin dose modifications, cumulative dose, CEAE grade, and visual acuity after bandage contact lens intervention. These outcomes cover different measures and follow-up questions. In general, examining multiple outcomes can create multiplicity: the more comparisons considered, the greater the opportunity for chance findings if all are interpreted as confirmatory. The registry record does not report an outcome hierarchy, multiplicity adjustment, or which analyses were designated confirmatory.

The record lists 0 analyses. This indicates that analysis results are not present in the registry record; it does not establish whether analyses were conducted outside the registry. The statistical analysis plan, test methods, covariate adjustments, interim analyses, and handling of repeated measurements are not reported in the registry record. The primary outcome definition is available, but no group-specific result or inferential estimate accompanies it.

The primary population requires randomized participants to have received at least 1 dose and to have at least 1 post-baseline assessment within 8 weeks for either LogMAR or CEAE. This is not described as an all-randomized-participant analysis irrespective of treatment receipt or measurement availability. The registry does not report the number of participants lacking the required assessments, the reasons for missing data, or the method used to classify participants with incomplete measurements. Sensitivity analyses and assumptions about missing outcomes are also not reported.

These omissions limit interpretation of both the magnitude and reliability of any apparent group difference. They do not establish that missing data or multiplicity caused bias; the information needed to assess those possibilities is not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: febrile neutropenia (8.3%), thrombocytopenia (8.3%), ulcerative keratitis (8.3%), pyrexia (8.3%), eye infection (8.3%).

The registry safety entries give, for each arm, a number at risk and a number affected by serious adverse events, a number at risk and a number affected by other adverse events, and a deaths count. For Standard Steroids, the serious-event figures are 14 at risk and 6 affected; the other-adverse-event figures are 14 at risk and 14 affected; deaths are 1. For Standard Steroids + Vasoconstrictor + Cold Compress, the corresponding figures are 12 and 4, 12 and 12, and 1. For Enhanced Steroids + Vasoconstrictor + Cold Compress, they are 12 and 4, 12 and 12, and 1.

The registry also lists serious adverse-event terms with percentages: FEBRILE NEUTROPENIA, THROMBOCYTOPENIA, ULCERATIVE KERATITIS, PYREXIA, EYE INFECTION, and PNEUMONIA are each listed as 8.3%. The denominator and term-specific event counts are not reported in the registry record. These percentages should therefore be read as the registry’s listed values, not as a basis for deriving counts or comparing risks across arms.

Safety summaries describe events recorded during the study; they do not by themselves establish that a particular intervention caused an event. The record does not provide further detail on event timing, severity beyond the serious-event classification, attribution, or statistical comparisons.

12. What the Result Does, and Does Not, Mean

The registry record documents a randomized study of strategies intended to manage ocular side effects among participants with EGFR-amplified glioblastoma receiving depatuxizumab mafodotin. It defines a primary endpoint based on the need for a management change within 8 weeks, using a visual-acuity threshold or a CEAE severity threshold. It also records three ophthalmologic strategy arms and a terminated study status.

What the record does not establish is whether one strategy had fewer participants requiring a management change, how large any difference was, or how precise an estimate might be. The primary endpoint values, arm-specific denominators for that endpoint, confidence intervals, and statistical tests are not reported in the registry record. No conclusion about comparative results can be drawn from the endpoint definition or from the study design alone.

The serious adverse-event summaries are descriptive entries. They list numbers at risk and affected in each group, deaths, and selected serious-event terms with percentages. Without fuller event details and a reported analysis, these figures do not establish causation or provide a complete account of comparative safety. The registry does not report attribution or the methods used to compare safety between strategies.

The study’s terminated status also needs to be interpreted narrowly. It indicates the status recorded in the registry, but the reason for termination and its consequences for data collection or analysis are not reported. The available record therefore supports statements about the study’s question, design, endpoint definition, and listed safety data, while leaving its efficacy-related and comparative statistical findings unresolved.

In general, a null or unreported result is not equivalent to evidence that strategies are identical. Conversely, a defined endpoint and randomized design do not demonstrate that a strategy is superior. The missing results prevent either conclusion from being drawn from this record.

13. Why This Trial Matters Statistically

This trial is statistically notable because its primary outcome combines an objective visual-acuity threshold with a graded ocular adverse-event threshold. That construction reflects a practical management question: whether ocular effects crossed a level defined as inadequate control. At the same time, a combined endpoint can conceal differences between its components. If group results were available, the overall percentage would need to be interpreted alongside information about which criterion participants met.

The endpoint also depends on a specified baseline and follow-up window. Visual-acuity decline is evaluated relative to baseline correction from the screening ophthalmology visit, and the event window is within 8 weeks after the initial dose. These choices define what counts as an event and which changes are relevant. They also make the assessment schedule and handling of incomplete measurements important for interpretation; those details are not reported in the registry record.

Randomization and a parallel-group design provide a framework for comparing strategies, but statistical evidence depends on the observed outcomes, uncertainty estimates, and analysis choices. The registry record does not report the primary results or analyses. Its status as terminated adds context, but no reason or explanation is recorded, so the statistical implications of termination cannot be determined.

The record also lists numerous secondary outcomes spanning vision, corneal events, treatment modifications, and dose exposure. In general, this breadth makes prespecification and multiplicity handling important when interpreting a collection of results. The registry does not report those methods, and it lists 0 analyses. As a result, the central statistical lesson is the distinction between a clearly described endpoint and evidence about its observed frequency or comparative effect: the former is available, while the latter is not reported.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific gaps limit interpretation. The primary endpoint is defined, but the registry does not report event counts, percentages by arm, effect estimates, confidence intervals, or statistical tests. It is therefore not possible to assess the observed frequency of management changes or the precision of a comparison among the ophthalmologic strategies.

The primary population definition requires treatment receipt and at least one post-baseline assessment in the specified window. The number of participants meeting this definition in each arm is not reported. Nor are reasons for missing assessment, the handling of participants with only one endpoint component measured, or any sensitivity analysis. The extent to which the primary population differed from all randomized participants cannot be evaluated from the record.

Some treatment-arm descriptions are incomplete. The standard steroid schedule is described, but the vasoconstrictor instructions for one arm end mid-description, and the enhanced-arm description is also truncated. This limits the ability to reconstruct the full intervention protocols from the registry record. The record does not report adherence or exposure to the ophthalmologic measures.

The study is listed as terminated, but the reason and timing of termination are not reported. The record does not explain whether termination affected enrollment, follow-up, or outcome availability. It also does not report a sample-size justification, statistical analysis plan, multiplicity strategy, interim analyses, or the method used to address missing data. These are unknowns, not evidence that a particular procedure was or was not used outside the registry record.

Finally, the safety entries provide summarized counts and selected serious-event terms, but the registry does not report attribution, timing, detailed event counts by term, or comparative safety analyses. These limits preclude a detailed assessment of safety patterns.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: UNITE Study: Understanding New Interventions With GBM ThErapy — NCT03419403.
• Registry record last updated 2021-04-14; status last verified 2021-03.
• Results first posted 2021-04-14.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03419403 is a randomized, open-label, parallel-group Phase 3b study, classified as PHASE3 in the registry, of ocular side-effect management strategies for participants with EGFR-amplified glioblastoma receiving depatuxizumab mafodotin. The listed arms use standard steroid drops, standard steroid drops with vasoconstrictor drops and a cold compress, or enhanced steroid measures with vasoconstrictor drops and a cold compress.

The primary endpoint is the percentage requiring a change in ocular side-effect management within 8 weeks after the initial dose, based on a visual-acuity decline threshold or CEAE severity threshold. Registry enrollment is 40; the study status is terminated. The registry lists 13 outcome measures and 0 analyses. Primary endpoint results and the reason for termination are not reported in the registry record.